SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 1,128.60 |
| Enterprise Value ($M) | 1,891.50 |
| Book Value ($M) | 2,660.35 |
| Book Value / Share | 12.26 |
| Price / Book | 0.42 |
| NCAV ($M) | -824.28 |
| NCAV / Share | -3.80 |
| Price / NCAV | -1.37 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.14 |
| Return on Assets (ROA) | -0.11 |
| Return on Equity (ROE) | -0.15 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.45 |
| Current Ratio | 3.91 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 551.71 |
| Assets | 4,036.34 |
| Liabilities | 1,375.99 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 14.30 | 24.52 | |
| 13G/A | Norges Bank | 6.80 | -18.59 | |
| 13G/A | Vanguard Group Inc | 10.85 | 20.48 | |
| 13G/A | Select Equity Group, L.P. | 4.30 | -29.04 | |
| 13G/A | Baillie Gifford & Co | 4.50 | ||
| 13G | William Blair Investment Management, Llc | 6.10 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 582,029 | 3,896,780 | 14.94 | |
| 578,781 | 5,835,887 | 9.92 | |
| 959,141 | 5,948,369 | 16.12 | |
| 781,641 | 5,923,820 | 13.19 | |
| 2,603,009 | 11,138,412 | 23.37 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MRVI – Maravai LifeSciences Holdings, Inc. | MYGN – Myriad Genetics, Inc. |
| NBIX – Neurocrine Biosciences, Inc. | NKTX – Nkarta, Inc. |
| NMRA – Neumora Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io